Kira Pharmaceuticals LLC

Akamis Bio is a clinical-stage oncology company based in Cambridge, MA, focused on leveraging their innovative Tumor Specific ImmunoGene Therapy (TSIGn) platform to improve the lives of individuals battling cancer. Their approach aims to harness the patient's immune system to recognize, attack, and eliminate solid tumors, particularly through the use of their viral vector-based therapeutics which specifically target tumor sites following intravenous delivery. The company's growing pipeline of TSIGn therapeutics is designed to drive the expression of therapeutic proteins that remodel the tumor microenvironment and elicit strong antitumor immune responses. This novel class of medicines holds potential for use both as monotherapy and in combination with other immuno-oncology agents, offering new hope to patients with difficult-to-treat solid tumors. Generated from the website

Ankyra Therapeutics Inc, based in Cambridge, MA, is a clinical-stage biotech company specializing in developing anchored-drug conjugates for triggering long-lasting anti-tumor responses while ensuring safety. By leveraging their expertise in drug development, the company aims to optimize anchored immunotherapy to enhance the lives of cancer patients. Their unique approach involves designing products with enhanced tumor retention, believing that prolonged drug presence in tumors leads to more significant clinical benefits. These anchored-drug conjugates are meticulously crafted to bind molecules to aluminum hydroxide, thereby extending anti-tumor immune activation, reducing systemic side effects, and requiring less frequent dosing for efficacy. Through their Anchored Immunotherapy platform, Ankyra Therapeutics focuses on creating anchored molecules to improve the safety profiles of drugs that face challenges due to dose-limiting toxicities. Their pipeline includes the promising ANK-101, an IL-12 anchored-drug conjugate exhibiting potent therapeutic activity in preclinical models and now undergoing evaluation in patients with advanced solid tumors. Generated from the website content

Immuneering Corporation, based in Cambridge, MA, is a biopharmaceutical company dedicated to developing medicines with broad activity for large patient populations. Their lead clinical stage candidate, IMM-1-104, aims to achieve universal-RAS activity against tumors driven by mutations in RAS and beyond, selectively impacting cancer cells more than healthy cells through deep cyclic inhibition of the MAPK pathway. With a robust pipeline of novel drug programs, Immuneering is advancing their differentiated approach to drug development, which aims to deprive tumor cells of sustained proliferative signaling while sparing healthy cells. Their proprietary disease-agnostic platform, integrating bioinformatics and computational biology, allows them to leverage human biological data in innovative ways, providing counterintuitive insights unconstrained by conventional approaches or prevailing scientific views.Generated from the website